Suppliers and packagers for generic pharmaceutical drug: brilliant blue g

brilliant blue g

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dutch Ophthalmic	TISSUEBLUE	brilliant blue g	SOLUTION;OPHTHALMIC	209569	NDA	D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.	68803-722-05	10 POUCH in 1 CARTON (68803-722-05) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS	2019-12-31

Brilliant Blue G: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

Brilliant Blue G (BBG) is a dye utilized in various medical applications, primarily as a diagnostic agent. Its use in visualizing anatomical structures, particularly during surgical procedures and diagnostic imaging, drives demand. Analysis of the supplier landscape reveals a concentrated market with a few dominant manufacturers. The patent landscape, while not characterized by extensive new filings, shows a historical pattern of development and application patents, with ongoing relevance for existing formulations and uses.

What are the primary suppliers of Brilliant Blue G?

The global supply of Brilliant Blue G is concentrated among a limited number of chemical manufacturers. These companies typically specialize in producing dyes and pharmaceutical intermediates. Their production capabilities and regulatory compliance are critical for ensuring a consistent and high-quality supply for the pharmaceutical industry.

• Sigma-Aldrich (Merck KGaA): A prominent supplier of laboratory chemicals and reagents, including Brilliant Blue G. They offer various grades suitable for research and potentially pharmaceutical development. Their global distribution network facilitates accessibility.
• Thermo Fisher Scientific: Another major supplier of scientific research equipment and consumables. Thermo Fisher Scientific provides Brilliant Blue G as part of its extensive chemical catalog, catering to research and analytical needs.
• Santa Cruz Biotechnology: Known for its antibody production, Santa Cruz Biotechnology also offers a range of biochemicals and reagents, including Brilliant Blue G, for research purposes.
• Avantor (VWR): A broad-spectrum supplier for life sciences and advanced technologies, Avantor, through its VWR channel, provides Brilliant Blue G. They serve academic, industrial, and governmental research laboratories.
• Specific Dye Manufacturers (e.g., Sun Chemical, DIC Corporation): While not always directly marketing to pharmaceutical end-users, larger industrial dye manufacturers may produce Brilliant Blue G as a bulk chemical, which is then supplied to pharmaceutical ingredient manufacturers or distributors. These entities operate on a larger scale and focus on industrial-grade production.

These suppliers differ in their target markets, with some focusing on research-grade materials and others capable of producing larger, pharmaceutical-grade quantities, contingent on regulatory certifications and Good Manufacturing Practice (GMP) compliance. The choice of supplier often depends on the specific application's purity requirements and regulatory demands.

What are the key applications and their patent relevance for Brilliant Blue G?

Brilliant Blue G's utility is primarily linked to its chromophoric properties, making it useful in visualizing biological tissues and fluids. Patent activity has historically focused on its formulation and specific diagnostic or surgical applications.

Surgical Visualization

BBG is used to identify and delineate specific anatomical structures during surgery, enhancing precision and reducing the risk of unintended tissue damage.

• Patent Focus: Patents in this area often claim methods of visualizing tissues or organs using BBG, specific concentrations, or combinations with other agents. Examples include visualizing the lymphatic system in sentinel lymph node biopsies, identifying fistulas, or marking surgical margins.
• Example: A patent might describe a method for mapping lymphatic drainage by injecting BBG at a specific site and detecting its presence in draining lymph nodes or vessels.

Diagnostic Imaging

BBG can serve as a contrast agent in certain diagnostic imaging techniques.

• Patent Focus: Patents may cover novel formulations of BBG for improved imaging contrast, stability, or reduced toxicity. Claims could also relate to specific imaging modalities where BBG provides superior visualization compared to existing agents.
• Example: Research into using BBG as a contrast agent for optical coherence tomography (OCT) or fluorescence imaging.

Pharmaceutical Research and Development

In R&D, BBG is used as a tool for cell viability assays and other biochemical studies.

• Patent Focus: While direct patents on BBG as a research tool are less common, patents may claim specific assays or experimental protocols that incorporate BBG for evaluating drug efficacy, toxicity, or cellular processes.
• Example: A patent for a novel drug screening platform that uses BBG to assess cell death induced by candidate compounds.

Formulation and Delivery

Innovations in how BBG is formulated and delivered can lead to patentable inventions.

• Patent Focus: This includes developing stable solutions, lyophilized powders, or nanoparticles that enhance BBG's bioavailability, targeting, or duration of action. Patents can also cover specific administration routes or devices for delivering BBG.
• Example: A patent for a sterile, ready-to-use solution of BBG with extended shelf-life for intraoperative use.

What is the current patent landscape for Brilliant Blue G?

The patent landscape for Brilliant Blue G is characterized by a mature core of foundational patents related to its synthesis and early applications. While new patent filings are not as prolific as for novel drug entities, there is continued activity in specific formulation improvements and specialized applications.

Historical Patenting Trends:

• Early Patents (pre-1980s): Focused on the synthesis and general properties of Brilliant Blue G, establishing its identity as a dye. These patents have long expired.
• Mid-Century Patents (1950s-1980s): Began exploring its use as a biological stain and diagnostic aid. Patents during this period would have detailed early applications in visualizing tissues and fluids.
• Late 20th and Early 21st Century Patents: Showed increasing specificity in application. This era saw patents related to its use in lymphangiography, surgical marking, and specific ophthalmological procedures. Innovations in sterile formulations for injection also emerged.

Current Patent Activity (Post-2010):

Current patent filings are less about the core molecule and more about optimizing its use.

• Composition of Matter: No significant new composition of matter patents are expected for Brilliant Blue G itself, as its chemical structure is well-established.
• Method of Use Patents: The majority of recent patent activity likely lies in new or improved methods of using Brilliant Blue G. This could involve:
  • Enhanced Surgical Guidance: Patents claiming specific protocols for visualizing different types of tissues or structures, or using BBG in conjunction with new surgical techniques or technologies.
  • Novel Diagnostic Applications: Exploring BBG's utility in imaging or diagnostic contexts not previously patented, potentially involving new detection methods.
  • Combinatorial Therapies/Diagnostics: Patents covering the co-administration or co-application of BBG with other agents for synergistic diagnostic or therapeutic effects.
  • Improved Formulations: While patents on basic formulations might be scarce, advancements in drug delivery systems (e.g., sustained release, targeted delivery using nanoparticles) could still yield patentable inventions involving BBG.

Key Patent Characteristics:

• Geographic Distribution: Patent filings are distributed globally, with significant activity in major pharmaceutical markets such as the United States, Europe, and Japan.
• Assignees: While academic institutions and independent inventors may contribute, a significant portion of patents is likely held by pharmaceutical companies, medical device manufacturers, and specialized chemical companies that leverage BBG in their product development.
• Lifespan: Many foundational patents have expired. However, patents covering specific formulations or methods of use developed more recently will have varying remaining terms. For example, a patent filed in 2015 with a 20-year term would be valid until 2035.

Analysis of Patent Databases:

A comprehensive review of patent databases (e.g., USPTO, EPO, WIPO) using keywords like "Brilliant Blue G," "patent," "method," "diagnostic," and "surgical" would reveal specific granted patents and pending applications. This would allow for precise tracking of patent expiry dates and the identification of key innovators and their intellectual property portfolios.

How does Brilliant Blue G's regulatory status impact its supply chain?

Brilliant Blue G's use in medical applications subjects it to stringent regulatory oversight, directly influencing its supply chain. The regulatory classification of BBG depends on its intended use.

• Active Pharmaceutical Ingredient (API) or Excipient: When used as a diagnostic agent administered to patients, BBG is treated as a drug substance or an integral component of a drug product. This necessitates compliance with Good Manufacturing Practice (GMP) guidelines.
  • Impact: Manufacturers must adhere to GMP standards for production, quality control, and documentation. This often requires specialized facilities, rigorous testing protocols, and detailed batch records. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee these aspects. The cost of GMP compliance can be substantial, limiting the number of suppliers capable of meeting these requirements.
• Research Use Only (RUO) Reagent: When sold for laboratory research and not for direct human or animal administration, BBG is classified as a RUO reagent.
  • Impact: This classification has less stringent manufacturing and quality control requirements compared to pharmaceutical-grade materials. RUO suppliers focus on purity and consistency for experimental reproducibility but are not bound by the same extensive regulatory frameworks as API manufacturers. This allows for a broader range of suppliers, including those focused on laboratory chemicals.
• Medical Device Component: In some instances, BBG might be considered a component of a medical device, such as an ink for surgical marking.
  • Impact: The regulatory pathway for medical devices varies by classification. If BBG is a critical component influencing the device's performance or safety, it may be subject to specific material qualification processes as part of the device's overall regulatory submission.

Key Regulatory Considerations:

• Purity Standards: Different applications demand different purity levels. Pharmaceutical-grade BBG requires very high purity, with strict limits on residual solvents, heavy metals, and related impurities. This directly affects manufacturing processes and analytical testing.
• Sterility: For injectable applications, BBG must be sterile and pyrogen-free. This requires aseptic processing or terminal sterilization, adding complexity and cost to manufacturing.
• Stability: Shelf-life and stability studies are critical for pharmaceutical applications. Suppliers must demonstrate that their BBG formulations remain stable under specified storage conditions.
• Traceability and Documentation: A robust supply chain requires complete traceability of raw materials, manufacturing processes, and quality control data. This is essential for regulatory compliance and product recalls if necessary.
• Import/Export Regulations: International trade of pharmaceutical ingredients is subject to import and export regulations, including potential tariffs and specific documentation requirements by customs agencies.

The regulatory environment dictates that suppliers aiming to serve the pharmaceutical market must invest significantly in quality systems and regulatory affairs. This often leads to a more consolidated supplier base for pharmaceutical-grade Brilliant Blue G compared to research-grade materials.

What are the market dynamics and pricing considerations for Brilliant Blue G?

The market for Brilliant Blue G is influenced by its specific applications, regulatory requirements, and the concentration of its supplier base.

Market Size and Growth Drivers:

• Surgical Procedures: The primary driver for pharmaceutical-grade BBG is its use in surgery. Growth in minimally invasive surgery, complex reconstructive procedures, and the increasing prevalence of conditions requiring precise tissue visualization contributes to demand.
• Diagnostic Imaging Advancements: While not a primary standalone contrast agent for major imaging modalities like MRI or CT, its niche applications in fluorescence-guided surgery or specific diagnostic tests can drive demand.
• Research and Development: The use of BBG in academic and industrial research laboratories for biological assays provides a consistent, albeit smaller, market segment.

Pricing Factors:

• Grade and Purity: Pharmaceutical-grade, GMP-compliant BBG commands significantly higher prices than research-grade material. This reflects the increased manufacturing costs, rigorous quality control, and regulatory documentation required.
• Volume: Bulk purchases typically benefit from lower per-unit pricing. However, the specialized nature of BBG's pharmaceutical applications may limit the scale of individual orders.
• Supplier Concentration: A concentrated supplier market, particularly for GMP-grade material, can lead to less price competition. The limited number of qualified manufacturers grants them some pricing leverage.
• Regulatory Compliance Costs: The ongoing costs associated with maintaining GMP certification, conducting stability studies, and fulfilling regulatory reporting requirements are factored into the pricing of pharmaceutical-grade BBG.
• Formulation Complexity: Specialized formulations, such as sterile solutions or specific concentrations, will be priced higher than the bulk chemical itself due to additional processing and quality assurance steps.

Competitive Landscape:

The competitive landscape is bifurcated:

• Research Grade: This segment is more competitive, with numerous chemical suppliers offering BBG at varying purities and price points.
• Pharmaceutical Grade: This segment is less competitive, dominated by a few manufacturers with established GMP capabilities and regulatory approvals. Competition here is often based on reliability of supply, quality assurance, and existing customer relationships rather than aggressive price wars.

Supply Chain Risks:

• Raw Material Availability: While BBG is synthesized from common chemical precursors, any disruption in the supply chain of these raw materials could indirectly impact BBG production.
• Manufacturing Disruptions: Production facilities are subject to operational risks (e.g., equipment failure, natural disasters, labor issues). For GMP-grade BBG, the impact of such disruptions is magnified due to the limited number of alternative suppliers.
• Regulatory Changes: Stricter regulatory requirements or changes in compliance standards could necessitate significant investment from suppliers, potentially leading to price increases or the exit of some smaller players.

Future Outlook:

The market for Brilliant Blue G is expected to remain stable, with moderate growth tied to advancements in surgical techniques and diagnostics. The key differentiator for suppliers will be their ability to consistently provide high-quality, regulatory-compliant material and ensure supply chain resilience.

Key Takeaways

• The Brilliant Blue G supply chain is concentrated, especially for pharmaceutical-grade material, with key suppliers including Sigma-Aldrich, Thermo Fisher Scientific, Santa Cruz Biotechnology, and Avantor.
• Demand is primarily driven by surgical visualization and diagnostic applications, with patent activity focusing on methods of use and formulation improvements rather than new composition of matter.
• Regulatory compliance, particularly GMP standards for pharmaceutical applications, significantly impacts supplier capabilities, pricing, and market access.
• Pricing is highly dependent on the grade of BBG, with pharmaceutical-grade material commanding a premium due to stringent quality and regulatory requirements.
• Supply chain risks are heightened due to the limited number of GMP-certified manufacturers.

FAQs

1. What is the primary use of Brilliant Blue G in medicine? Brilliant Blue G is primarily used in medicine as a diagnostic agent and surgical dye to visualize anatomical structures and fluids, aiding in surgical precision and diagnosis.

2. Are there many manufacturers producing pharmaceutical-grade Brilliant Blue G? No, the number of manufacturers producing pharmaceutical-grade Brilliant Blue G is limited due to the stringent Good Manufacturing Practice (GMP) requirements and regulatory oversight involved.

3. How long are patents for new methods of using Brilliant Blue G typically valid? Patents for new methods of using Brilliant Blue G, like other pharmaceutical patents, typically have a term of 20 years from the filing date, subject to potential extensions.

4. Does the regulatory status of Brilliant Blue G differ between research and clinical use? Yes, Brilliant Blue G intended for research use is classified as "Research Use Only" and has less stringent regulatory requirements than Brilliant Blue G intended for clinical administration, which must meet pharmaceutical-grade standards.

5. What factors most significantly influence the price of Brilliant Blue G? The grade and purity of Brilliant Blue G, particularly whether it meets pharmaceutical-grade and GMP compliance standards, is the most significant factor influencing its price.

Citations

[1] Merck KGaA. (n.d.). Sigma-Aldrich Product Catalog. Retrieved from [Manufacturer's website, specific URL if available, otherwise general company website] [2] Thermo Fisher Scientific. (n.d.). Thermo Fisher Scientific Product Catalog. Retrieved from [Manufacturer's website, specific URL if available, otherwise general company website] [3] Santa Cruz Biotechnology. (n.d.). Santa Cruz Biotechnology Product Catalog. Retrieved from [Manufacturer's website, specific URL if available, otherwise general company website] [4] Avantor, Inc. (n.d.). VWR Product Catalog. Retrieved from [Manufacturer's website, specific URL if available, otherwise general company website] [5] U.S. Food and Drug Administration. (n.d.). Guidance Documents. Retrieved from [FDA website, specific URL if available, otherwise general FDA website on regulations] [6] European Medicines Agency. (n.d.). Regulatory Guidance. Retrieved from [EMA website, specific URL if available, otherwise general EMA website on regulations]